← 홈

Antibody

136개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 136개
AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleIsofol Medical ABPhase 2

ARFOX + bevacizumab (arfolitixorin, arfolitixorin (ARFOX + bevacizumab))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

bevacizumab+chemotherapy (bevacizumab+chemotherapy)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

capecitabine and oxaliplatin + cetuximab (capecitabine and oxaliplatin + cetuximab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 1

cetuximab and lapatinib (cetuximab and lapatinib)

Colorectal Cancer; Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

cetuximab with irinotecan (cetuximab with irinotecan)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 5%임상시험 1상태 DISCONTINUED
AntibodystaleEli LillyPhase 2

cetuximab-containing chemotherapy (cetuximab-containing chemotherapy)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

cetuximab/irinotecan/simvastatin (cetuximab/irinotecan/simvastatin)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

fulzerasib; cetuximab N01 (fulzerasib; cetuximab N01)

Colorectal Cancer; KRAS G12C Mutant Advanced Solid Tumors · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBeijing HospitalPhase 2

irinotecan, cetuximab, envafolimab (irinotecan, cetuximab, envafolimab)

RAS Mutation; Metastatic Colorectal Cancer · RAS Mutation

#RASMutation#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSpanish Cooperative Group for t…Phase 2

mFOLFOX-6 + cetuximab until disease progression or early withdrawal. (mFOLFOX-6 + cetuximab until disease progression or early withdrawal.)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleFudan UniversityPhase 3

mFOLFOX6 + Cetuximab (mFOLFOX6 + Cetuximab)

Colorectal Cancer; Liver Metastases · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

modifiedFOLFOX6 + Cetuximab (modifiedFOLFOX6 + Cetuximab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleChinese PLA General HospitalPhase 2

oxaliplatin+capecitabine+bevacizumab+PD-1 antibody (oxaliplatin+capecitabine+bevacizumab+PD-1 antibody)

Colorectal Cancer; RAS Mutation · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleUniversity of UtahPhase 1

regorafenib + panitumumab (regorafenib + panitumumab)

KRAS and NRAS Wild-type Colorectal Cancer · KRAS and NRAS Wild-type Colorectal Cance

#KRASandNRASWild-typeColorectalCa#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleFudan UniversityPhase 2

standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab (standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab)

Microsatellite Stable Metastatic Colorectal Cancer · Microsatellite Stable Metastatic Colorec

#MicrosatelliteStableMetastaticCo#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

7 / 7 페이지

← 이전다음 →